CASTLEFORD, England,
June 27, 2012 /PRNewswire/ --
We are pleased to announce the launch of generic Ibandronic Acid
150mg film-coated tablets.
(Photo:
http://photos.prnewswire.com/prnh/20120627/540216 )
Ibandronic Acid is a generic version of Bonviva®
(Ibandronic Acid) from Roche. It is indicated in the
treatment of osteoporosis in postmenopausal women at increased risk
of fracture (see section 5.1 of SPC for further
details)[1].
Ibandronic Acid is available immediately in the award-winning
Teva 360 livery as follows:
Strength and pack size 150mg x 1 150mg x 3
Brand Price GBP18.40 GBP55.21
Initial Teva retail price GBP12.88 GBP38.65
Kim Innes, Commercial Director at
Teva, said: "We've now launched 21 products this year including ten
on day one of patent expiry, in a variety of strengths and pack
sizes."
New or existing customers can order through their local Teva
Territory Sales Manager, through major wholesalers, or call
0800-085-8621
To find out more about Teva UK Limited, visit
http://www.tevauk.com.
Notes to Editors:
About Teva UK Limited
Teva UK Limited is one of the UK's top ten pharmaceutical
manufacturers, with a presence in the generics, branded respiratory
and hospitals markets. It has the widest range of any UK generic
pharmaceutical company and markets solid and liquid dose,
injectable and respiratory medicines to healthcare professionals.
The company is part of Teva Pharmaceutical Industries Ltd.
About Teva Pharmaceutical Industries
Ltd
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading
global pharmaceutical company, committed to increasing access to
high-quality healthcare by developing, producing and marketing
affordable generic drugs as well as innovative and specialty
pharmaceuticals and active pharmaceutical ingredients.
Headquartered in Israel, Teva is
the world's leading generic drug maker, with a global product
portfolio of more than 1,300 molecules and a direct presence in
about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as
well as biologics. Teva currently employs approximately 46,000
people around the world and reached $18.3
billion in net revenues in 2011.
1. A reduction in the risk of vertebral fractures has been
demonstrated; efficacy on femoral neck fractures has not been
established.
For media enquiries, contact the Teva UK Limited Media team on
+44(0)1977-628500, or email media.enquiries@tevauk.com.